检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:安智[1] 贺巧艳[1] 郑娜[1] AN Zhi;HE Qiaoyan;ZHENG Na(Department of Nephrology,Affiliated Hospital of Yan'an University,Yan'an Shanxi 716000,China)
机构地区:[1]延安大学附属医院肾内科,陕西延安716000
出 处:《空军医学杂志》2021年第6期506-509,共4页Medical Journal of Air Force
基 金:中华医学会临床医学科研专项资金项目(14010090546)。
摘 要:目的分析血清抗磷脂酶A2受体抗体(anti-phospholipase A2 receptor, PLA2R-Ab)与膜性肾病(membranous nephropathy,MN)临床疗效的关系。方法选取延安大学附属医院住院治疗的50例MN患者和门诊体检的50例健康人员作为研究对象,均进行血清PLA2R-Ab、肾功能指标检测,Spearman相关性分析PLA2R-Ab阳性率与MN病理分期的相关性。结果观察组血清PLA2R-Ab水平、24 h尿白蛋量均高于对照组,观察组白蛋白、内生肌酐清除率均低于对照组(P<0.05)。结论 MN患者经治疗后显效率越高,血清PLA2R-Ab水平越低,血清PLA2R-Ab水平降低意味着病情缓解,血清PLA2R-Ab水平增高预示疾病复发,故加强血清PLA2R-Ab检测,在MN患者疾病诊断、疗效评估中具有重要价值。Objective To analyze the relationships between levels of PLA2 R-Ab and the clinical efficacy of MN(membranous nephropathy). Methods Fifty cases of MN patients(the observation group) who were hospitalized in our hospital and another 50 healthy physical examinees(the control group) in the outpatient clinic were selected as the subjects.Serum levels of PLA2 R-Ab and renal function indexes were detected. Spearman correlation analysis was used to analyze the positive rate of PLA2 R-Ab and the correlations with pathological staging of MN. Results The levels of serum PLA2 RAb and 24 h urinary protein were higher in the observation group than in the control group, but the levels of Alb and Ccr were lower(P<0.05). Conclusion The higher the effective rate of MN patients after treatment, the lower the serum level of PLA2 R-Ab, suggesting the remission of the disease. The increase in the serum PLA2 R-Ab level indicates the recurrence of the disease. Therefore, the serum PLA2 R-Ab test is critical, which is of significant value in the diagnosis of MN patients and in the assessment of the curative effect.
关 键 词:膜性肾病 抗磷脂酶A2受体抗体 治疗效果 相关性
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15